3 Medicines and Lab Testing Stocks With a Strong Future Roadmap: Aurobindo Pharma, Lincoln Pharmaceuticals and Suraksha Diagnostic

Aurobindo Pharma Rs 1,693.00, P/E 25.46. Lincoln Pharma Rs 558.30, P/E 11.64. Suraksha Diagnostic Rs 316.25, P/E 46.05. Closing prices of 9 Oct 2026.

Updated: 12 Oct 2026 • 12:20 pm

Posted by:

3 Medicines and Lab Testing Stocks With a Strong Future Roadmap: Aurobindo Pharma, Lincoln Pharmaceuticals and Suraksha Diagnostic

Quick Answer

Medicines and lab testing stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients, Lincoln Pharma in formulations for India and emerging markets and Suraksha Diagnostic in pathology and diagnostic testing. FY26 revenue growth was 5.6% at Aurobindo Pharma, 9.1% at Lincoln Pharma and 22.5% at Suraksha Diagnostic. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 46.05 for Suraksha Diagnostic (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Medicines and lab testing stocks give investors exposure to medicines, ingredients and lab tests that families and doctors use every day. Volume growth, product mix and margins decide how much of that demand turns into profit.

This list covers three medicines and lab testing stocks: Aurobindo Pharma for generic formulations and active ingredients, Lincoln Pharmaceuticals for formulations for India and emerging markets and Suraksha Diagnostic for pathology and diagnostic testing. Every figure comes from the latest reported financials and the 9 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Medicines and Lab Testing Stocks?

Medicines and lab testing stocks are shares of companies that make medicines or run diagnostic labs. Results depend on volume growth, product mix and margins, so product mix and margins separate the stronger names.

Medicines and Lab Testing Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three medicines and lab testing stocks as of the 9 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Aurobindo Pharma	1,693.00	94,477	25.46	37.59	9.25%	0.21
Lincoln Pharmaceuticals	558.30	1,123	11.64	37.59	11.60%	0.01
Suraksha Diagnostic	316.25	1,614	46.05	62.79	13.15%	0.53

Among pharma and diagnostics stocks, all three trade at a discount to their industry P/E multiples.

Why Do Medicines and Lab Testing Stocks Have a Strong Roadmap in India?

Medicines and lab testing stocks have a strong roadmap in India because health spending keeps rising with ageing, insurance cover and more tests, which supports both medicine makers and diagnostic chains. Three drivers stand out.

Healthcare spending: More families use medicines and tests regularly.
Export reach: Generic makers sell in the US, Europe and emerging markets.
Preventive testing: Wider health checks raise diagnostic volumes.

Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg

Aurobindo Pharma's roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.

Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.

Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.

Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg

Lincoln Pharma's roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.

Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.

Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Suraksha Diagnostic: Diagnostic Labs Drive the Pipeline

Suraksha Diagnostic's roadmap rests on diagnostic and pathology testing through a network of labs and collection centres, with rising health screening supporting test volumes.

Revenue grew from Rs 225.50 crore in FY22 to Rs 313.58 crore in FY26, a 39.1% rise, and FY26 revenue was 22.5% higher than FY25. FY26 net profit rose 1.4% to Rs 31.40 crore. Over four years, net profit rose from Rs 23.75 crore in FY22 to Rs 31.40 crore. In Q1 FY27, revenue grew 20.7% to Rs 88.74 crore, and net profit rose 40.0% to Rs 12.85 crore. Operating margin was 32.01% in FY26 and 35.97% in Q1 FY27 against 33.97% a year earlier.

Debt to equity is 0.53 and return on equity is 13.15%. FY26 operating cash flow was Rs 81.83 crore against capital expenditure of Rs 67.34 crore. Suraksha Diagnostic paid a dividend of Rs 0.05 per share for FY26, a yield of 0.02%. At a P/E of 46.05 against an industry P/E of 62.79, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 35.97% against 32.01% for FY26, so margin stability is the figure to follow as volumes grow.

Best Medicines and Lab Testing Stocks in India: Aurobindo Pharma vs Lincoln Pharma vs Suraksha Diagnostic on Key Financials

Among the best medicines and lab testing stocks in India, Aurobindo Pharma ranks second on the lowest P/E and the lowest debt to equity; Lincoln Pharma leads on FY26 net profit growth and the lowest P/E; Suraksha Diagnostic leads on FY26 revenue growth and Q1 FY27 revenue growth. The table puts the numbers side by side.

Metric	Aurobindo Pharma	Lincoln Pharma	Suraksha Diagnostic
FY26 revenue (Rs Cr)	34,145.17	704.48	313.58
FY26 revenue growth	5.6%	9.1%	22.5%
FY26 net profit (Rs Cr)	3,502.97	87.89	31.40
FY26 net profit growth	0.6%	6.7%	1.4%
Q1 FY27 revenue growth (YoY)	18.1%	19.0%	20.7%
Q1 FY27 net profit growth (YoY)	25.2%	30.9%	40.0%
Return on equity	9.25%	11.60%	13.15%
P/E ratio	25.46	11.64	46.05
Debt to equity	0.21	0.01	0.53
Dividend yield	0.25%	0.32%	0.02%

Healthcare earnings follow volume growth, product mix and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Medicines and Lab Testing Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen medicines and lab testing stocks and shortlist medicines and lab testing stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check margins and growth in the main markets or test volumes together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these medicines and lab testing stocks

Risks to Consider Before Investing in Medicines and Lab Testing Stocks

Pricing pressure: Generic prices can affect margins.
Regulatory checks: Inspections can affect plant or lab operations.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, Lincoln Pharma and Suraksha Diagnostic live.

Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.

Final Take: Which Stock Has the Strongest Roadmap?

These three pharma and diagnostics stocks cover generic medicines, branded formulations and diagnostic testing. Aurobindo Pharma ranks second on the lowest P/E and the lowest debt to equity; Lincoln Pharma leads on FY26 net profit growth and the lowest P/E; Suraksha Diagnostic leads on FY26 revenue growth and Q1 FY27 revenue growth.

Across medicines and lab testing stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the medicines and lab testing stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Medicines and Lab Testing Stocks

Which are the best medicines and lab testing stocks in India with a strong roadmap?

Ans. Aurobindo Pharma, Lincoln Pharmaceuticals and Suraksha Diagnostic stand out for their roadmaps in generic medicines, branded formulations and diagnostic testing. FY26 revenue growth was 5.6% at Aurobindo Pharma, 9.1% at Lincoln Pharma and 22.5% at Suraksha Diagnostic, and return on equity ranges from 9.25% to 13.15%.

Is Aurobindo Pharma a good stock to buy now?

Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, pricing and regulatory checks move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Aurobindo Pharma, Lincoln Pharma and Suraksha Diagnostic?

Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 11.64 for Lincoln Pharma (industry 37.59) and 46.05 for Suraksha Diagnostic (industry 62.79). All of them trade below the industry multiple.

Which of these medicines and lab testing stocks has the highest return on equity?

Ans. Suraksha Diagnostic has the highest return on equity at 13.15%, followed by Lincoln Pharmaceuticals at 11.60% and Aurobindo Pharma at 9.25%.

What are the risks of investing in medicines and lab testing stocks?

Ans. The main risks are pricing pressure, regulatory checks and quarterly trends. Generic prices can affect margins.

How did Aurobindo Pharma, Lincoln Pharma and Suraksha Diagnostic perform in Q1 FY27?

Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. Suraksha Diagnostic reported revenue of Rs 88.74 crore, up 20.7% year on year, and net profit rose 40.0% to Rs 12.85 crore.

Do medicines and lab testing stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.25% for Aurobindo Pharma, 0.32% for Lincoln Pharma and 0.02% for Suraksha Diagnostic, based on dividends declared for FY26.

How can I invest in medicines and lab testing stocks in India?

Ans. You can buy medicines and lab testing stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.